EyePoint Pharmaceuticals, Inc. (EYPT)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 11.84 |
| Open | 11.84 |
| Bid | 12.05 x 100 |
| Ask | 12.15 x 600 |
| Day's Range | 11.79 - 12.33 |
| 52 Week Range | 5.67 - 30.99 |
| Volume | |
| Avg. Volume | 1,187,941 |
| Market Cap | 632.305M |
| Beta (5Y Monthly) | 1.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.81 |
| Earnings Date | Jul 31, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.44 |
GuruFocus.comInsider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT)
On May 14, 2024, David Guyer, Director at EyePoint Pharmaceuticals Inc (NASDAQ:EYPT), executed a sale of 11,625 shares of the company.
GlobeNewswireEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an a
GuruFocus.comEyePoint Pharmaceuticals Q1 2024 Earnings: Revenue Surpasses Estimates Despite Challenges
Comprehensive Analysis of Financial Performance and Strategic Developments
© 2024 Yahoo. All rights reserved.